Previous 10 | Next 10 |
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evalu...
2023-11-26 04:55:05 ET Summary XEN1101 shows clinical promise in epilepsy and MDD, with Phase 3 trials critical for its broader efficacy evaluation. Financially, Xenon faces a stark YOY revenue drop and rising R&D costs but maintains strong liquidity and cash runway. Marke...
2023-11-09 16:56:54 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To...
VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced that its partner, Neurocrine Biosciences, Inc., reported today that the Phase 2 clinical trial evaluating NBI-921352 in adult patients ...
2023-11-08 20:59:08 ET Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Results Conference Call November 08, 2023 04:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Of...
2023-11-08 16:28:41 ET More on Xenon Pharma Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity Xenon Is Well-Funded Heading Into Key Readouts Seeking Alpha’s Quant Rating on Xenon Pharma Historica...
Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late November to mid-December XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizur...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Xenon Pharmaceuticals Inc. (XENE) is expected to report $-0.75 for Q3 2023
2023-11-07 17:35:57 ET More on Xenon Pharma Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity Seeking Alpha’s Quant Rating on Xenon Pharma Historical earnings data for Xenon Pharma For further de...
News, Short Squeeze, Breakout and More Instantly...
Xenon Pharmaceuticals Inc. Company Name:
XENE Stock Symbol:
NASDAQ Market:
Xenon Pharmaceuticals Inc. Website:
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical...
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Cli...
2024-05-15 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...